Laetrile Case Histories

Laetrile Case Histories presents a collection of 62 patient case histories from the Richardson Cancer Clinic, documenting the experiences of individuals who pursued Laetrile (also marketed or referred to as “Vitamin B17” or amygdalin) as part of their approach to cancer.

Written by John A. Richardson, M.D. and Patricia Irving Griffin, R.N., B.S., the book examines individual diagnoses, prognoses, treatment experiences, and outcomes as reported by the authors. Many of the individuals profiled were reportedly given limited life expectancies before seeking treatment at the Richardson Cancer Clinic.

This updated edition also includes follow-up information approximately 30 years after the original diagnoses, giving readers an opportunity to revisit the long-term outcomes of individuals whose stories appeared in the original work.

For readers interested in the history of alternative cancer therapies, Laetrile research, the Richardson Cancer Clinic, and the controversy surrounding amygdalin, Laetrile Case Histories offers a firsthand historical perspective through the patient accounts documented by its authors.

Inside the Book:

• 62 individual patient case histories
• Accounts from the Richardson Cancer Clinic
• Reported diagnoses, prognoses, treatment experiences, and outcomes
• Follow-up information spanning approximately three decades
• Historical insight into the use and controversy surrounding Laetrile and amygdalin

Authors: John A. Richardson, M.D. & Patricia Irving Griffin, R.N., B.S.

Please Note: This book presents historical case reports and the views, observations, and conclusions of its authors. It is offered for informational and historical purposes only and should not be interpreted as medical advice, a recommendation for any treatment, or evidence that Laetrile or amygdalin is effective in diagnosing, treating, curing, or preventing cancer. Laetrile/amygdalin is not FDA-approved for the treatment of cancer.